



EDELIRIS announces medicinal chemistry collaboration with MUTABILIS

Lyon – May 14th, 2007 – EDELIRIS announced today that it has signed an agreement to accelerate MUTABILIS' medicinal chemistry efforts towards one of their kinase targets. The collaboration will include a combination of Edelris' recognized medicinal chemistry expertise and resources with innovative, natural-mimetic Keymical Collections™.

"EDELIRIS is pleased to actively contribute to MUTABILIS' outstanding team in its novel drug discovery and development efforts," said Jean-Yves Ortholand, CEO of EDELIRIS. "Our scientists are looking forward to working with their counterparts to optimise MUTABILIS' proprietary molecules for their antiinfective programs."

"Pharmaceutical research collaborations with competent external partners are important to accelerate in-house drug discovery knowledge and experience. EDELIRIS' track record, client-oriented mindset and flexibility are what gave us the confidence to work with them, thus enabling collaboration with the highest professionalism and quality standards." Said Dr.Sonia Escaich, CEO of MUTABILIS.

Financial terms of the collaboration were not disclosed.

About Mutabilis:

MUTABILIS is a biopharmaceutical company, founded in 2001 and specializing in antibacterial drug discovery. The company's focus is to create a new class of anti-infectious drugs by developing molecules with new mechanisms of action.

A new antibacterial concept called anti-virulence is used to discover new drugs that selectively aim at pathogenic bacteria as soon as they spread via the bloodstream or extra cellular fluids, without preventing the proliferation of bacteria of the normal flora. This new scientific approach addresses major unmet medical needs of the 21st century: new antibacterial drugs active against resistant strains and new therapies for hospital-acquired infections.

About Edelris:

EDELIRIS is a MedChem-oriented Research & Service based company, dedicated to the design and production of innovative, therapeutically relevant, natural-mimetic screening compounds. Aiming at the acceleration of the hit/lead discovery process in pharmaceutical and biotech research organizations, EDELIRIS uses its track-proven chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit/lead optimization capabilities.

Several customers from pharmaceutical and biotechnology companies worldwide have already recognized the value and specificity of Edelris offer, accessing either its experienced MedChem services or its innovative natural-mimetic Keymical Collections™.